# Stage 6 Remediation Changelog

## Scope
This change set hardens the Stage 6 clinical reporting gateway to a fail-closed, CLIA/CAP/NY-aligned posture for release packaging, provenance retention, and regulated reporting controls. The remediation addresses concrete integrity, validation, and auditability gaps while preserving a strict DSL2 execution boundary and immutable evidence trail.

## 1. Multi-sample collision and manifest assembly hardening

### Fixed item
- Multi-sample manifest assembly was hardened to prevent cross-sample contamination in the final merged Stage 6 manifest.
- The final manifest assembly now validates each fragment before consolidating outputs, requiring sample IDs, component contract fields, and complete artifact references for every Stage 6 output.

### Regulatory / fail-closed justification
- In a regulated clinical pipeline, a manifest that silently mixes outputs from multiple samples can produce misattribution and downstream reporting errors.
- Requiring the presence of all required Stage 6 fields and enforcing exact artifact existence protects the traceability chain from partial or ambiguous packaging.
- This supports patient identity integrity, report fidelity, and the ability to reconstruct a complete evidence trail for regulated review.

## 2. Verifiable Stage 5 signature enforcement

### Fixed item
- Added an explicit Stage 5 signature verification gate before downstream clinically actionable reporting proceeds.
- The verification logic canonicalizes the clinical payload, recomputes the expected SHA256 digest, and rejects a mismatch before the reporting chain continues.

### Regulatory / fail-closed justification
- A release payload that has been modified after signing is not clinically trustworthy; the correct safety posture is to stop the pipeline rather than continue with unverifiable content.
- This is the minimum standard for a signed clinical artifact: detect tampering at the point of handoff and prevent unsigned or altered payloads from being incorporated into downstream report generation.
- The fail-closed behavior directly supports auditability, chain-of-custody expectations, and SaMD release integrity under CLIA/CAP/NY expectations.

## 3. Reference manifest and preflight status validation

### Fixed item
- Hardened Stage 6 precondition validation so `preflight_lock` and `preflight_lock_status` are required as raw, explicit tokens and are not treated as path-like values or indirectly resolved file paths.
- The precondition guard verifies the lock status equals the required approved token before allowing progress into Stage 6 reporting.

### Regulatory / fail-closed justification
- The preflight lock is a regulatory control gate: if the status is missing, incorrect, or misinterpreted, the system must reject the release rather than operate on an uncertain basis.
- Treating the value as a path-like artifact is a contract bug that can silently undermine the validity of the preflight gate; the corrected behavior preserves the intended control semantics.
- This keeps the system aligned with fail-closed clinical release logic and prevents the pipeline from proceeding when the environment or metadata contract is not compliant.

## 4. Manifest and metadata hardening for regulated output assembly

### Fixed item
- The Stage 6 manifest assembly logic was hardened to reject unresolved template literals, missing fixed fields, malformed metadata, and absent regulated artifacts.
- It now validates the presence and shape of required JSON fragments and rejects work products that do not satisfy the release contract.

### Regulatory / fail-closed justification
- In regulated bioinformatics, a missing or malformed field is equivalent to incomplete evidence: a downstream review should not be able to infer regulatory completeness from partial data.
- Fail-closed metadata validation prevents unreviewed outputs from being packaged into the final release bundle.
- This is essential for a defensible audit record and for ensuring that the produced Stage 6 manifest is reproducible and reviewable.

## 5. FMEA coverage for clinically relevant failure modes

### Fixed item
- The Stage 6 FMEA harness now exercises the key negative cases:
  - corrupt Stage 5 validation token rejection
  - signature mismatch rejection
  - candidate VUS disparity detection
  - missing reference mount fallback behavior
  - missing regulated metadata rejection
- The suite verifies success/failure expectations with exact fatal-code assertions where applicable.

### Regulatory / fail-closed justification
- FMEA coverage is a core control for demonstrating that the system behaves safely when confronted with failure injections.
- Verifying the exact fail-fast behavior for signature tampering and missing regulated metadata is a direct demonstration that the pipeline does not continue in a non-compliant state.
- This evidence is essential for internal validation, release readiness review, and post-hoc investigation when a clinical deployment or audit question arises.

## 6. Final artifact integrity packaging

### Fixed item
- Added a Stage 6 release finalizer that computes SHA256 digests for all final report artifacts and emits `Stage6_SHA256SUMS.txt`.
- The integrity manifest is included as part of the final Stage 6 release packaging output.

### Regulatory / fail-closed justification
- Integrity manifests are the formal evidence that each final artifact was generated and preserved without silent mutation after packaging.
- This is particularly important for controlled release environments, where the final artifact set must be reproducibly auditable and reviewable.
- It enables artifact validation, release comparison, and formal evidence retention without requiring the original pipeline execution context.

## Summary
The Stage 6 remediation closes the gaps between pipeline execution logic and clinical release controls by ensuring:
- only signed Stage 5 bundles enter the reporting chain,
- metadata and preflight gates are validated as explicit tokens,
- manifest assembly rejects incomplete or malformed evidence,
- negative FMEA scenarios are proven in execution, and
- final artifacts are packaged with SHA256 provenance.

This establishes a defensible, fail-closed posture for the Stage 6 reporting workflow while maintaining a strict DSL2 workflow boundary and leaving a complete immutable audit trail.
